SpectraCure (SPEC) Q4 2024 earnings summary

Executive summary

• Focused on advancing clinical studies for primary localized and recurrent prostate cancer, including a new agreement with Memorial Sloan Kettering Cancer Center in New York.

• Q-PRO® system and PDT method aim to offer minimally invasive, individualized cancer treatment with fewer side effects.

• Positive early clinical results show expected necrosis without damage to surrounding tissue; safety confirmed by DSMB.

• Patent portfolio strengthened with new approval in Japan; ongoing efforts to expand clinical studies in Europe.

• Annual ISO 13485:2016 certification maintained, supporting global market approval processes.

Financial highlights

• Q4 2024 net loss after tax: -4,646 TSEK (Q4 2023: -4,373 TSEK); EPS: -0.05 SEK (unchanged year-over-year).

• Full-year 2024 net loss after tax: -23,004 TSEK (2023: -20,441 TSEK); EPS: -0.24 SEK (2023: -0.21 SEK).

• Cash flow from operating activities: -5,766 TSEK in Q4 (Q4 2023: -2,003 TSEK); -21,826 TSEK for the year (2023: -18,680 TSEK).

• Cash and cash equivalents at year-end: 18,274 TSEK (2023: 56,951 TSEK).

• Operating expenses for the year remained stable at 39,737 TSEK (2023: 39,961 TSEK).

Outlook and guidance

• Ongoing preparations to treat first patients in the primary localized prostate cancer study; expansion to Europe planned.

• Current liquidity expected to fund operations until summer 2025; additional capital will be required for continued clinical studies.

• Strategy includes seeking international financing and partnerships as clinical evidence grows.